Catalent

CTLT | NYSE | 2 Followers

$63.48

0.00%

$0.00

Overview Metrics Financials

Fair Price

$57.63

Overvalued by 64.8%

To display the fair price of a share, you need to be a member of Bulios Black.

Company Quality

Profitability Score

14/100

Solvency Score

49/100

Dividends

Dividends data currently unavailable.

Earnings

Earnings data currently unavailable.

My Notes

You haven't added any notes for this stock yet. Use this space to record your insights or strategies.

Profile

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Mr. Alessandro Maselli

CEO

17000

Employees

Somerset

Headquarters

Country

Catalent, Inc. (CTLT) is an American pharmaceutical company specializing in the development and manufacturing of drugs, biologics, and medical devices. With a wide range of services including drug formulation, clinical trials, manufacturing, and packaging, Catalent provides comprehensive solutions for pharmaceutical and biotechnology companies worldwide. The company is known for its emphasis on innovation and quality, enabling it to enhance biopharmaceutical research and accelerate the market introduction of new products. Catalent also invests in advanced technologies and expands its manufacturing capacities to meet the growing demand for specialized healthcare solutions. Catalent, Inc. (CTLT) shares could be suitable for investors looking for opportunities in the pharmaceutical sector with a focus on the production and development of biological and pharmaceutical products.

Key Metrics TTM

Valuation

Market cap.

$12B

Enterprise Value

$16B

Price to Earnings

-27.97

Price to Sales

2.61

Price to Book

3.26

Price to Cash Flow

116.4

Profitability

Return on Assets

-4.25%

Return on Equity

-11.44%

Return on Invested Capital

0.76%

Gross Margin

21.82%

Operating Margin

1.27%

Net Margin

-9.34%

Liquidity

Quick Ratio

1.96

Current Ratio

2.51

Cash Ratio

0.34

Inventory Turnover

6.25

Asset Turnover

0.46

Total Liabilities

$6.2B

Solvency

Debt to Assets

0.51

Debt to Equity

N/A

Interest Coverage

0.22

Equity Ratio

0.36

Long-term Debt to Cap.

0.58

Altman Z-Score

1.62

Performance

Earnings Waterfall

Debt level and coverage

Earnings

Feed

There are no posts to show right now.